<li>acebutolol<p>escitalopram increases levels of acebutolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>almotriptan<p>escitalopram, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>atenolol<p>escitalopram increases levels of atenolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>betaxolol<p>escitalopram increases levels of betaxolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>bisoprolol<p>escitalopram increases levels of bisoprolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>bumetanide<p>bumetanide, escitalopram. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>carvedilol<p>escitalopram increases levels of carvedilol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>celandine<p>celandine decreases effects of escitalopram by pharmacodynamic antagonism. Minor/Significance Unknown. Based on animal studies.</p></li><li>celiprolol<p>escitalopram increases levels of celiprolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of escitalopram by decreasing metabolism. Minor/Significance Unknown.</p></li><li>eletriptan<p>escitalopram, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>esmolol<p>escitalopram increases levels of esmolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>ethacrynic acid<p>ethacrynic acid, escitalopram. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>felodipine<p>felodipine will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>frovatriptan<p>escitalopram, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>furosemide<p>furosemide, escitalopram. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>labetalol<p>escitalopram increases levels of labetalol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>lithium<p>escitalopram, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity.</p></li><li>methylphenidate<p>methylphenidate increases effects of escitalopram by decreasing metabolism. Minor/Significance Unknown.</p></li><li>metoprolol<p>escitalopram increases levels of metoprolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>nadolol<p>escitalopram increases levels of nadolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>naratriptan<p>escitalopram, naratriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>nebivolol<p>escitalopram increases levels of nebivolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>panax ginseng<p>panax ginseng increases effects of escitalopram by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>parecoxib<p>parecoxib will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>penbutolol<p>escitalopram increases levels of penbutolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>pindolol<p>escitalopram increases levels of pindolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>pleurisy root<p>pleurisy root decreases effects of escitalopram by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>propranolol<p>escitalopram increases levels of propranolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>rizatriptan<p>escitalopram, rizatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>simeprevir<p>escitalopram decreases levels of simeprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>sotalol<p>escitalopram increases levels of sotalol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>sumatriptan<p>escitalopram, sumatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan intranasal<p>escitalopram, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan transdermal<p>escitalopram, sumatriptan transdermal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>timolol<p>escitalopram increases levels of timolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>torsemide<p>torsemide, escitalopram. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>zolmitriptan<p>escitalopram, zolmitriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li>